Dublin, Feb. 22, 2018 (GLOBE NEWSWIRE) -- The "Global Hepatitis B Virus [HBV] Treatment Market - Analysis By Type (Therapeutics, Vaccine), By End User (Male, Female) - By Region, By Country: Opportunities and Forecast (2017-2022)" report has been added to ResearchAndMarkets.com's offering.

The global market is projected to display a growth represented by a CAGR of 5.30% by value during 2017 - 2022, chiefly driven by increase in healthcare spending and improving access to diagnosis for Chronic Hepatitis B, increasing risk of severe complications due to Hepatitis B virus.

Over the recent years, the global Hepatitis B Treatment industry has been driven by the increasing number of patients diagnosed with Chronic Hepatitis B which results in severe complications, rising awareness about the consequences of viral infection, rigorous efforts to eliminate the viral infection, improving surveillance and diagnostic facilities, significant number of drugs in pipeline with better efficacy coupled with emerging vaccines with lower dosage and better effectiveness. Globally, the growth in Hepatitis B Treatment market is driven by backed by growing middle class population group demanding better drugs to improve lifestyle.

Among the type of treatment, therapeutics accounts for the major market share and anticipated to witness significant growth rate during the forecast period. Among the regions, Asia Pacific is predicted to advance at the highest rate, mainly driven by large population suffering with chronic Hepatitis B virus with unfulfilled need, improving access to healthcare, changing lifestyle and expanding middle class income group.

Scope of the Report

Global Market (Actual Period: 2012-2016, Forecast Period: 2017-2022)

• Global Hepatitis B Treatment Market
• Analysis By Type (Therapeutics and Vaccines)
• Analysis By End-User (Male and Female)

Regional Markets - North America, Europe, APAC, ROW (Actual Period: 2012-2016, Forecast Period: 2017-2022)

• By Type (Therapeutics and Vaccines)
• By End-User (Male and Female)

Country Analysis - United States, Canada, United Kingdom, Germany, France, China, India, Japan (Actual Period: 2012-2016, Forecast Period: 2017-2022)

• By Type (Therapeutics and Vaccines)
• By End-User (Male and Female)

Other Report Highlights

• Market Dynamics - Trends, Drivers, Challenges, Policy and Regulation
• Company Analysis - Merck and Co; Gilead Sciences; Novartis AG; GlaxoSmithKline, plc; Hoffmann- La Roche; Bristol-Myers Squibb

Key Topics Covered:

1. Research Methodology

2. Executive Summary

3. Strategic Recommendations

4. Hepatitis B Treatment Market: Product Outlook

5. Global Hepatitis B Treatment Market: Growth and Forecast

6. North America Hepatitis B Treatment Market: Growth and Forecast

7. Europe Hepatitis B Treatment Market: Growth and Forecast

8. Asia-Pacific Hepatitis B Treatment Market: Growth and Forecast

9. ROW Hepatitis B Treatment Market: Growth and Forecast

10. Market Dynamics

11. Market Restraints

12. SWOT Analysis - Hepatitis B Treatment Market

13. Porter's Five Forces Analysis

14. Policy and Regulations

15. Global Hepatitis B Drugs Pipeline

16. Global Hepatitis B Treatment Market - Competitive Landscape

17. Company Profiles

• Merck and Co
• Gilead Sciences
• Novartis AG
• GlaxoSmithKline plc
• Hoffmann
• La Roche
• Bristol-Myers Squibb

For more information about this report visit https://www.researchandmarkets.com/research/xfxcl9/global_hepatitis?w=12

CONTACT: ResearchAndMarkets.com
         Laura Wood, Senior Manager
         press@researchandmarkets.com
         For E.S.T Office Hours Call 1-917-300-0470
         For U.S./CAN Toll Free Call 1-800-526-8630
         For GMT Office Hours Call +353-1-416-8900
         Related Topics: Infectious Diseases Drugs, Liver and Kidney Disorders Drugs